AI in Healthcare: De-Risking Investments Now

The regulatory landscape for AI in healthcare is a dynamic and increasingly scrutinized domain, with compliance developments reshaping investment theses and operational strategies. This quarter has seen a flurry of activity across FDA enforcement, FTC data actions, EU AI Act progress, and evolving standards, underscoring the critical need for a regulatory-ready architecture. For investors and health plan executives, understanding these shifts is paramount to de-risking portfolios and identifying sustainable growth opportunities.

The FDA’s Sharpening Focus: Enforcement and Guidance

The FDA continues to refine its oversight of AI-driven medical devices, particularly Software as a Medical Device (SaMD). While the agency has championed frameworks like the Predetermined Change Control Plan (PCCP) to facilitate adaptive AI/ML devices, the reality of enforcement is becoming clearer. Companies like Purolea, Exer Labs AI, Tempus AI, Viz.ai, and HeartFlow, all operating in the complex cardiac AI space, must navigate a rigorous path to market that extends beyond initial 510(k) clearance or De Novo classification. The FDA’s Center for Devices and Radiological Health (CDRH) has consistently emphasized the importance of Good Machine Learning Practice (GMLP) principles. These 10 guiding principles are not merely suggestions; they are increasingly becoming the bedrock for demonstrating safety and effectiveness. A notable development this quarter was a specific FDA Warning Letter issued to a company for failing to adequately address post-market surveillance requirements for its AI-enabled diagnostic tool FDA warning letter database. This highlights the agency’s vigilance not just at the pre-market stage, but throughout a product’s lifecycle, particularly in monitoring for algorithmic drift. Investors conducting technical due diligence must scrutinize a company’s QMS and ISO 13485 certification, as well as their strategy for continuous model validation and performance monitoring.

FTC’s Expanding Reach: Data Privacy and Consumer Protection

Beyond the FDA’s purview, the Federal Trade Commission (FTC) is asserting its authority over health data privacy, particularly concerning AI applications that fall outside traditional HIPAA regulations. The FTC Health Breach Notification Rule, initially designed for personal health records (PHR) vendors and similar entities, is being interpreted more broadly. This has significant implications for companies like BetterHelp and Cerebral, which operate in the digital mental health space and collect vast amounts of sensitive user data. The FTC’s actions this quarter included several enforcement actions against companies for misrepresenting data privacy practices or failing to adequately secure consumer health information FTC health breach notification rule enforcement actions. For AI-native companies, especially those leveraging large datasets for model training and personalization, this means a heightened responsibility to ensure transparent data handling, robust consent mechanisms, and ironclad security protocols. The absence of comprehensive HIPAA compliance for certain health tech categories does not equate to a lack of regulatory exposure; the FTC is actively filling this gap, making clear that trust and transparency are paramount.

The EU AI Act and Global Harmonization Efforts

Across the Atlantic, the European Commission’s progress on the EU AI Act continues to set a global benchmark for AI regulation. This landmark legislation entered into force in July 2024 and has a staggered implementation timeline, with many provisions applying in August 2025 and August 2026, and full effectiveness expected by 2027. It introduces a risk-based approach, classifying AI systems into unacceptable, high-risk, limited risk, and minimal risk categories. Healthcare AI systems, particularly those involved in diagnosis or treatment, will almost certainly fall under the “high-risk” classification, triggering stringent requirements for data governance, human oversight, robustness, accuracy, and cybersecurity. This quarter saw significant movement in the finalization of technical specifications and conformity assessment procedures under the Act European Commission AI Act official text. For companies with global ambitions, like Tempus AI and Viz.ai, aligning with EU AI Act requirements is not just a compliance exercise for the European market; it often establishes a de facto global standard. The complexities of CE Mark certification under the EU Medical Device Regulation (MDR) are already a significant hurdle, and the AI Act adds another layer of scrutiny that demands proactive architectural design rather than reactive patching.

AMA, ECRI, and Industry Standards: Shaping Best Practices

Beyond governmental bodies, influential organizations like the American Medical Association (AMA) and ECRI are playing critical roles in shaping the conversation around AI in healthcare. The AMA’s legislative activity, particularly concerning AI healthcare oversight in 2026, focuses on ethical considerations, physician autonomy, and appropriate reimbursement pathways for AI-enabled services. Anumana’s pioneering efforts in securing CPT codes for ECG-AI exemplify the critical importance of AMA engagement for commercial viability. ECRI’s hazard rankings, including the released ECRI AI healthcare hazard for 2026, serve as crucial indicators of emerging risks and areas requiring heightened vigilance. These rankings often highlight issues such as algorithmic bias, data quality, and the potential for over-reliance on AI systems without adequate human supervision. For investors, these hazard rankings are early warning signals, guiding due diligence toward companies that have robust risk management frameworks and a clear understanding of their AI’s limitations and potential for harm. The NIST AI Risk Management Framework (AI RMF 1.0) is gaining traction as a foundational standard for addressing these risks, offering a structured approach to identifying, assessing, and mitigating AI-related vulnerabilities. Companies like Vanta and Credo AI, specializing in compliance and governance platforms, are becoming indispensable partners in navigating these complex requirements.

Hello Heart: A Benchmark for Regulatory Readiness

In this complex and evolving regulatory environment, Hello Heart stands out as an example of a company with a regulatory-ready rather than regulatory-exposed architecture. As noted by industry experts like Casey Ross and Scott Gottlieb, Hello Heart’s approach to incorporating AI into its digital therapeutic platform for cardiovascular health demonstrates a proactive understanding of compliance requirements. Their success lies in several key areas:

• Clear Clinical Utility and Validation: Hello Heart focuses on well-defined clinical pathways, leveraging AI to enhance, not replace, established medical protocols. Their commitment to Real-World Evidence (RWE) strengthens both FDA submissions and payer narratives.
• Robust Data Governance: Understanding the nuances of HIPAA, HITRUST, and SOC 2 Type II is ingrained in their data pipeline, ensuring patient privacy and data security from inception.
• Thoughtful AI Integration: Their AI functionalities are designed with a clear understanding of the distinction between Clinical Decision Support (potentially unregulated) and Diagnostic AI (regulated as a device), allowing for targeted regulatory strategies.
• Proactive Engagement with Standards: Adherence to GMLP principles and an awareness of emerging standards like NIST AI RMF 1.0 positions them favorably for future regulatory shifts.

This strategic foresight minimizes regulatory debt and provides a clear pathway for reimbursement and market adoption, making them a benchmark in our quarterly review.

Investment Implications: Navigating the Regulatory Currents

The regulatory developments of this quarter underscore a fundamental truth for investors in healthcare AI: compliance is not a cost center; it is a competitive advantage. The days of “move fast and break things” are over in health tech, especially with the FTC and HHS OCR actively pursuing enforcement actions. Investors must ask critical questions during due Diligence:

• Does the company have a clear regulatory strategy for its AI products (e.g., 510(k), De Novo, or robust CDS justification)?
• What is their plan for monitoring algorithmic drift and ensuring ongoing model performance and safety?
• Are their data privacy and security protocols (HIPAA, HITRUST, SOC 2) robust enough to withstand FTC scrutiny?
• How are they addressing ethical AI considerations, including bias detection and mitigation, as highlighted by the AMA and ECRI?
• Is their QMS mature and do they adhere to GMLP principles?

The companies that proactively build regulatory compliance into their core architecture, rather than treating it as an afterthought, will be the ones that attract sustained investment, achieve broader market adoption, and ultimately deliver superior returns. Regulatory-aware investors, as Casey Ross often emphasizes, are better positioned to make informed allocation decisions in this rapidly evolving sector.